Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 15 for:    Recruiting, Not yet recruiting Studies | Batten Disease

A Natural History Study of Late Infantile Variant CLN5 And CLN7 Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03822650
Recruitment Status : Recruiting
First Posted : January 30, 2019
Last Update Posted : October 14, 2020
Sponsor:
Information provided by (Responsible Party):
Neurogene Inc.

Brief Summary:

CLN5 and CLN7 are forms of Batten Disease, and neurodegenerative disorders in children causing psychomotor regression, seizures, blindness, loss of ambulation and premature death, and have no available treatments.

The purpose of this study is to investigate the clinical characteristics and natural clinical progression of symptoms in individuals with CLN5 and CLN7. This natural history study is important to better understand disease course to be able to determine clinically relevant outcome measures for use in future clinical trials.


Condition or disease
Ceroid Lipofuscinosis, Neuronal 5 Ceroid Lipofuscinosis, Neuronal 7

Detailed Description:

Neuronal Ceroid Lipofuscinosis (NCL) are comprised of a group of fatal neurodegenerative diseases caused by mutations in an enzyme or protein which results in the accumulation of toxic deposits in the eye, brain, skin, muscle and other cells.

CLN5 is a type of NCL, caused by homozygous or bi-allelic heterozygous variants in the CLN5 gene. Lack of CLN5 protein impairs the breakdown of certain proteins, leads to defective lysosomal trafficking, resulting in accumulation of toxic material and subsequent cell damage. CLN5 disease presents in childhood with neurological findings including motor clumsiness and attention disturbances, followed by progressive visual failure, psychomotor depression, epilepsy, and premature death.

CLN7 is another type of NCL caused by homozygous or bi-allelic heterozygous variants in CLN7/MFSD8 gene, whose function is poorly characterized. CLN7 presents with neurological signs, including blindness, seizures, progressive deterioration in intellectual and motor capabilities, culminating in premature death in the first or second decade of life.

No investigational product will be provided in the study.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Natural History and Outcome Measure Discovery Study of Variant Late Infantile Neuronal Ceroid Lipofuscinosis Type 5 (CLN5) and Variant Late Infantile Neuronal Ceroid Lipofuscinosis Type 7 (CLN7)
Actual Study Start Date : March 13, 2019
Estimated Primary Completion Date : June 2026
Estimated Study Completion Date : December 2026





Primary Outcome Measures :
  1. Unified Batten Disease Rating Scale (UBDRS) [ Time Frame: 5 years ]
    Disease-specific clinical assessment used to assess physical, seizure, behavioral and functional capabilities. For physical assessments scores range from 0 to 4 with the score of 4 being most severe.

  2. Late Infantile Neuronal Ceroid Lipofuscinosis Rating Scale (Hamburg Scale) [ Time Frame: 5 years ]
    Disease specific tool used to capture 4 domains including motor function, seizures, visual function and language. Each sub-scale can be scored from 0-3 points in which 0 represents loss of function.


Secondary Outcome Measures :
  1. Electroencephalography (EEG) [ Time Frame: 5 years ]
    EEG records electrical brain activity and Interictal discharges (location, focal/generalized, etc) will be compared to baseline and characterized over time.

  2. Vineland Adaptive Behavior Scale, 2rd or 3rd Edition (Vineland-II, Vineland-3) [ Time Frame: 5 years ]
    Standard assessment measuring communication, socializing, and daily living skills to assess their overall adaptive functioning for individuals up to 90 years of age. A higher score generally corresponds with higher adaptive function.

  3. NEPSY, 2nd Edition (NEPSY-2) * [ Time Frame: 5 years ]
    Neuropsychological assessment to evaluate language skills for individuals 3-16 years of age.

  4. Woodcock-Johnson-IV Tests of Cognitive Abilities (WJ-IV)* [ Time Frame: 5 years ]
    Evaluates strengths and weaknesses among cognitive abilities in subjects 2-90 years of age. A higher score generally corresponds with higher function.

  5. Bayley Scales of Infant and Toddler Development Test, 3rd edition (Bayley-3) * [ Time Frame: 5 years ]
    Developmental test that measures cognitive, language, motor, and social-emotional domains of infants and young children between 1 and 42 months of age. A higher score generally corresponds with higher function.


Biospecimen Retention:   Samples With DNA
whole blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with a confirmed genetic diagnosis of CLN5 or CLN7.
Criteria

Inclusion Criteria:

  • Participants must have a diagnosis of CLN5 or CLN7 based on clinical presentation and genetic testing (known or suspected pathogenic mutation in CLN5 or CLN7/MFSD8 gene).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03822650


Contacts
Layout table for location contacts
Contact: Contact Center 877-237-5020 medicalinfo@neurogene.com

Locations
Layout table for location information
United States, New York
University of Rochester Medical Center Recruiting
Rochester, New York, United States, 14642
Contact: Amy Vierhile, RN    585-275-4762    amy_vierhile@urmc.rochester.edu   
Sponsors and Collaborators
Neurogene Inc.
Investigators
Layout table for investigator information
Study Director: Elise Beausoleil Neurogene Inc.
Layout table for additonal information
Responsible Party: Neurogene Inc.
ClinicalTrials.gov Identifier: NCT03822650    
Other Study ID Numbers: STU-2018-0226
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: October 14, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Neurogene Inc.:
CLN
NCL
Batten
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuronal Ceroid-Lipofuscinoses
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Lipidoses
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Lipid Metabolism Disorders
Metabolic Diseases